Cargando…
No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients
BACKGROUND AND PURPOSE: Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434592/ https://www.ncbi.nlm.nih.gov/pubmed/28287044 http://dx.doi.org/10.1080/17453674.2017.1300745 |
_version_ | 1783237078263267328 |
---|---|
author | Ledin, Håkan Good, Lars Johansson, Torsten Aspenberg, Per |
author_facet | Ledin, Håkan Good, Lars Johansson, Torsten Aspenberg, Per |
author_sort | Ledin, Håkan |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fixation. We used radiostereometric analysis (RSA) to investigate whether teriparatide influences prosthesis fixation. Early migration as measured by RSA can predict future loosening. PATIENTS AND METHODS: In a randomized controlled trial with blind evaluation, 50 patients with osteoarthritis of the knee were allocated to a teriparatide treatment group (Forsteo, 20 μg daily for 2 months postoperatively) or to an untreated control group. RSA was performed postoperatively and at 6 months, 12 months, and 24 months. The primary effect variable was maximal total point motion (MTPM) from 12 to 24 months. RESULTS: Median maximal total point motion from 12 to 24 months was similar in the 2 groups (teriparatide: 0.14 mm, 10% and 90% percentiles: 0.08 and 0.24; control: 0.13 mm, 10% and 90% percentiles: 0.09 and 0.21). [Authors: this is perhaps better than using "10th" and "90th", which looks ugly in print./language editor] The 95% confidence interval for the difference between group means was −0.03 to 0.04 mm, indicating that no difference occurred. INTERPRETATION: We found no effect of teriparatide on migration in total knee replacement. Other trials using the same dosing have suggested a positive effect of teriparatide on human cancellous fracture healing. Thus, the lack of effect on migration may have been due to something other than the dose. In a similar study in this issue of Acta Orthopaedica, we found that migration could be reduced with denosumab (Ledin et al. 2017). The difference in response between the anabolic substance teriparatide and the antiresorptive denosumab suggests that resorption has a more important role during the postoperative course than any deficit in bone formation. |
format | Online Article Text |
id | pubmed-5434592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-54345922017-06-01 No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients Ledin, Håkan Good, Lars Johansson, Torsten Aspenberg, Per Acta Orthop Knee BACKGROUND AND PURPOSE: Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fixation. We used radiostereometric analysis (RSA) to investigate whether teriparatide influences prosthesis fixation. Early migration as measured by RSA can predict future loosening. PATIENTS AND METHODS: In a randomized controlled trial with blind evaluation, 50 patients with osteoarthritis of the knee were allocated to a teriparatide treatment group (Forsteo, 20 μg daily for 2 months postoperatively) or to an untreated control group. RSA was performed postoperatively and at 6 months, 12 months, and 24 months. The primary effect variable was maximal total point motion (MTPM) from 12 to 24 months. RESULTS: Median maximal total point motion from 12 to 24 months was similar in the 2 groups (teriparatide: 0.14 mm, 10% and 90% percentiles: 0.08 and 0.24; control: 0.13 mm, 10% and 90% percentiles: 0.09 and 0.21). [Authors: this is perhaps better than using "10th" and "90th", which looks ugly in print./language editor] The 95% confidence interval for the difference between group means was −0.03 to 0.04 mm, indicating that no difference occurred. INTERPRETATION: We found no effect of teriparatide on migration in total knee replacement. Other trials using the same dosing have suggested a positive effect of teriparatide on human cancellous fracture healing. Thus, the lack of effect on migration may have been due to something other than the dose. In a similar study in this issue of Acta Orthopaedica, we found that migration could be reduced with denosumab (Ledin et al. 2017). The difference in response between the anabolic substance teriparatide and the antiresorptive denosumab suggests that resorption has a more important role during the postoperative course than any deficit in bone formation. Taylor & Francis 2017-06 2017-03-13 /pmc/articles/PMC5434592/ /pubmed/28287044 http://dx.doi.org/10.1080/17453674.2017.1300745 Text en © 2017 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. https://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0) |
spellingShingle | Knee Ledin, Håkan Good, Lars Johansson, Torsten Aspenberg, Per No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients |
title | No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients |
title_full | No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients |
title_fullStr | No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients |
title_full_unstemmed | No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients |
title_short | No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients |
title_sort | no effect of teriparatide on migration in total knee replacement: a randomized controlled trial involving 50 patients |
topic | Knee |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434592/ https://www.ncbi.nlm.nih.gov/pubmed/28287044 http://dx.doi.org/10.1080/17453674.2017.1300745 |
work_keys_str_mv | AT ledinhakan noeffectofteriparatideonmigrationintotalkneereplacementarandomizedcontrolledtrialinvolving50patients AT goodlars noeffectofteriparatideonmigrationintotalkneereplacementarandomizedcontrolledtrialinvolving50patients AT johanssontorsten noeffectofteriparatideonmigrationintotalkneereplacementarandomizedcontrolledtrialinvolving50patients AT aspenbergper noeffectofteriparatideonmigrationintotalkneereplacementarandomizedcontrolledtrialinvolving50patients |